Compass reports its psilocybin depression drug shows long-lasting benefits
For years, the promise of psychedelic medicine has run into the same hard question: even if a single dose lifts depression quickly, does the effect last? Compass Pathways, one of the most closely watched companies in the field, said its experimental treatment produced benefits that endured, a claim that speaks directly to that doubt. The update was reported by STAT News as part of its biotech coverage.
Compass is developing a synthetic form of psilocybin, the active compound in psychedelic mushrooms, delivered in a controlled clinical setting alongside psychological support. The therapeutic idea is that a small number of supervised sessions could produce durable improvement in treatment-resistant depression, a condition defined by its failure to respond to conventional antidepressants.
Durability is the pivotal issue because rapid relief has never been the sticking point. Trials of psychedelics and related compounds have repeatedly shown fast, sometimes dramatic reductions in depressive symptoms. The unresolved question has been whether patients stay better, or whether the benefit fades within weeks and requires repeat dosing, which would complicate the treatment model and its economics.
By reporting long-lasting benefits, Compass is addressing the field's central vulnerability head-on. If supervised psilocybin sessions can hold depression at bay for an extended period, the treatment becomes far more practical and more attractive to regulators and payers than a therapy that must be frequently repeated. That is why this particular readout drew attention beyond the company's own investors.
The context is a difficult stretch for psychedelic biotech. Earlier setbacks across the sector, including regulatory caution about trial design and questions over how to blind studies when patients can obviously tell whether they received a mind-altering drug, have tempered the early exuberance. A credible durability signal from a leading company is the kind of result the field has been waiting for.
Several caveats apply. Company-reported results are not the same as fully peer-reviewed, published data, and the details of how benefit was measured, over what period and in how many patients, determine how much weight the claim can bear. Depression trials are also notoriously sensitive to placebo effects, which are especially hard to control in studies of a drug with unmistakable subjective effects.
The blinding problem deserves emphasis because it is the methodological knot at the heart of psychedelic research. In a standard drug trial, neither patient nor doctor knows who received the active compound. With a psychedelic, participants usually know, and that awareness can inflate reported improvement through expectation alone. Researchers have proposed various designs to address this, but none fully solves it, which is why independent, long-term data matter so much.
There is also the practical shape of the treatment. Unlike a daily pill, supervised psilocybin therapy requires trained clinicians, monitored sessions and follow-up support, a model that is more resource-intensive than writing a prescription. Even strong efficacy would leave open questions about cost, access and how such a therapy would fit into overstretched mental-health systems.
Still, the significance of a durability claim from Compass is hard to overstate for patients with few options. Treatment-resistant depression is, by definition, the population that conventional medicine has failed, and for them a therapy offering lasting relief from a small number of sessions would be transformative. That potential is exactly why the sector attracts both intense investment and intense scrutiny.
The responsible reading is cautious optimism. Compass's report is an encouraging data point in a field that has needed one, but the decisive test will be detailed, independently reviewed results showing not just that benefits last, but for how long, for whom, and how reliably. Until then, the news marks progress on the question that matters most, without yet settling it.
Read next
Social care in England: public to be asked who should pay, as major review begins
The public will be asked who should pay for adult social care as part of a major government review in England, led by Baroness Louise Casey, who has called the current system "impossible". Here is what the review covers and why funding care has defied a fix for decades.
Drinking to cope with stress: how early alcohol use may rewire the brain, explained
A new study finds that using alcohol to cope with stress at a young age may permanently alter the brain, making it harder to adapt and raising the risk of relapse. Researchers also reported signs of brain damage linked to early dementia. Here is what the findings mean.
Can AI be trusted for skincare advice? What dermatologists say about chatbot diagnoses
People increasingly send selfies to AI chatbots for skincare analysis and rash diagnoses, but dermatologists warn there are more than 3,000 skin conditions and the tools can be unreliable. Here is what AI skin advice can and cannot safely do.
ApoB vs LDL: why millions may be getting the wrong cholesterol test, explained
A new study argues that apoB, a blood test that counts harmful cholesterol particles, predicts heart attacks and strokes better than the standard LDL cholesterol number, and remains cost-effective. Here is how the two tests differ and why it matters for who gets treated.
Testosterone: why men's average levels have halved in 50 years, and what the science says
Total testosterone in men fell 54% between 1972 and 2019, researchers told a European fertility meeting in London, warning of a male reproductive health crisis linked to obesity and diabetes. Here is what the data shows, what it does not, and why levels are declining.